| 发明名称 | Duocarmycin ADCS showing improved in vivo antitumor activity | ||
| 摘要 | The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumors with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC). | ||
| 申请公布号 | US9421278(B2) | 申请公布日期 | 2016.08.23 |
| 申请号 | US201514859201 | 申请日期 | 2015.09.18 |
| 申请人 | Synthon Biopharmaceuticals B.V. | 发明人 | Dokter Willem;Goedings Peter Johannes;Verheijden Gijsbertus Franciscus Maria;Beusker Patrick Henry |
| 分类号 | A61K47/48;A61K39/395;C07D405/12;A61K45/06;C07K16/40;A61K39/00 | 主分类号 | A61K47/48 |
| 代理机构 | Sterne, Kessler, Goldstein & Fox P.L.L.C. | 代理人 | Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| 主权项 | 1. A method of treating triple negative breast cancer in a human patient, comprising administering to the patient a therapeutically effective amount of a compound having the structure wherein 2.5-2.9 represents an average DAR for the compound. | ||
| 地址 | Nijmegen NL | ||